Trial · NCT00271609
Bevacizumab for Recurrent Malignant Glioma
NCT00271609, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2012-06-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bevacizumab for Recurrent Malignant Glioma. Trials, record NCT00271609. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00271609
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bevacizumab for Recurrent Malignant Glioma
- NCT number
- NCT00271609
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 88 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Recurrent High-Grade Gliomas, Malignant Gliomas
- Interventions
- Bevacizumab
- First posted
- 2006-01-02
- Last updated
- 2014-04-29
- Results first posted
- 2012-06-08
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Progression Free Survival at 6 Months. | 6 months | Percentage of participants surviving without progression of disease after six months of study entry. Progression is defined as a 25% increase in lesions, clear worsening of any evaluable disease, or appearance of any new lesion/site (e.g. by computed tomography, magnetic resonance imaging), or failure to return for evaluation due to death or deteriorating condition. |
| Primary | Number of Participants With Adverse Events | 5 years | Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Progression Free Survival at 6 Months. | 6 months | at the time of data cutoff for this endpoint, 31 patients in the AG arm and 48 patients in the GBM arm were evaluable for PFS. | Percentage of participants | NUMBER |
| PRIMARY | Number of Participants With Adverse Events | 5 years | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Progression Free Survival at 6 Months. | Anaplastic Glioma (AG) | 20.9 | 95% Confidence Interval 10.3 to 42.5 | Percentage of participants | |
| Percentage of Participants With Progression Free Survival at 6 Months. | Glioblastoma Multiforme (GBM) | 29 | 95% Confidence Interval 18 to 48 | Percentage of participants | |
| Number of Participants With Adverse Events | Anaplastic Glioma (AG) | 32 | Participants | ||
| Number of Participants With Adverse Events | Glioblastoma Multiforme (GBM) | 51 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Glioblastoma Multiforme (GBM) | 56 | |
| Overall Study | STARTED | Anaplastic Glioma (AG) | 32 | |
| Overall Study | COMPLETED | Glioblastoma Multiforme (GBM) | 43 | |
| Overall Study | COMPLETED | Anaplastic Glioma (AG) | 29 | |
| Overall Study | NOT COMPLETED | Glioblastoma Multiforme (GBM) | 13 | |
| Overall Study | NOT COMPLETED | Anaplastic Glioma (AG) | 3 |
Source ClinicalTrials.gov
Adverse events390
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Vascular disorders | Anaplastic Glioma (AG) | 9 | 32 | 12 |
| other | Hypertension | Vascular disorders | Glioblastoma Multiforme (GBM) | 11 | 56 | 12 |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | Anaplastic Glioma (AG) | 11 | 32 | 15 |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | Glioblastoma Multiforme (GBM) | 11 | 56 | 13 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Anaplastic Glioma (AG) | 2 | 32 | 2 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Glioblastoma Multiforme (GBM) | 5 | 56 | 6 |
| other | AST, SGOT (serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Anaplastic Glioma (AG) | 11 | 32 | 14 |
| other | AST, SGOT (serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Glioblastoma Multiforme (GBM) | 18 | 56 | 28 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Anaplastic Glioma (AG) | 3 | 32 | 6 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Glioblastoma Multiforme (GBM) | 10 | 56 | 13 |
1 to 10 of 390Source ClinicalTrials.gov
See all 390 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Anaplastic Glioma (AG) | ||
| Total, all-cause mortality | Glioblastoma Multiforme (GBM) | ||
| Total, other adverse events | Anaplastic Glioma (AG) | 32 | 32 |
| Total, other adverse events | Glioblastoma Multiforme (GBM) | 51 | 56 |
| Total, serious adverse events | Anaplastic Glioma (AG) | 11 | 32 |
| Total, serious adverse events | Glioblastoma Multiforme (GBM) | 24 | 56 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Anaplastic Glioma (AG) vs Glioblastoma Multiforme (GBM): Number of Participants With Adverse Events | Trial comparisons |
| Anaplastic Glioma (AG) vs Glioblastoma Multiforme (GBM): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00271609
GET https://conductscience.org/api/trials/v1/NCT00271609/events?page=2